Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicalutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Bicalutamide SCHEMBL5365801 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1561110 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL29353850 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL3611 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL3612 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL29354880 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (S)-Bicalutamide SCHEMBL29444530 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL28262190 | 0.98 | AR (0.96) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL679554 | 0.97 | AR (0.94) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL15325704 | 0.93 | AR (0.87) | ARCYP2C19ABCB11ALBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2678359-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | Merrimack Pharmaceuticals, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012116317-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| CN-101284795-B | Non-steroidal male hormone receptor regulating agent and medical uses thereof | SHANGHAI INST MATERIA MEDICA | 2012-04-25 | — | — | CN | disclosed |
| WO-2011064663-A1 | COMBINATION TREATMENT EMPLOYING BELINOSTAT AND BICALUTAMIDE | FESTUCCIA, CLAUDIO (IT) | 2011-06-03 | — | — | WO | disclosed |
| CN-101735267-A | Water-soluble (R)-(-)-bicalutamide pre-medicament, preparation method and application thereof | SHANGHAI SUN SAIL PHARMACEUTIC | 2010-06-16 | — | — | CN | disclosed |
| CN-101284795-A | Non-steroidal male hormone receptor regulating agent and medical uses thereof | SHANGHAI INST MATERIA MEDICA (CN) | 2008-10-15 | — | — | CN | disclosed |
| EP-1261363-B1 | METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS | SPECIALITY EUROP PHARMA LTD (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | IGF1R, CHEK2, MCL1 | AR 637/4885CYP2C19 4714/4885ABCB11 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.